Using two independent breast cancer patient‐derived tumor xenograft (PDX) panels, we assessed the antitumor activity of three PARPi and showed the potential of an immunostaining assay of the HRR protein RAD51 to predict PARPi sensitivity. The gene discussed is RAD51; the disease is neoplasm.